文献速递淋巴瘤造血干细胞移植与细胞治疗

既往CAR T细胞治疗对复发或难治性B细胞淋巴瘤患者莫妥珠单抗疗效的影响

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
PubMed 文献 · Blood Adv · 2025-01-01

本研究利用曾接受CAR-T治疗后参加莫妥珠单抗1/2期研究的患者临床数据和血样,分析30例有配对样本的患者。结果发现缓解者从CAR-T至莫妥珠单抗的中位时间显著长于未缓解者(P=0.006,未校正多重比较),且缓解者淋巴细胞计数更高、CD4和CD8细胞增加更多;未缓解者CAR转基因水平相对下降。这些发现提示既往CAR-T与双特异性抗体结局存在交互作用。

要点

  • 缓解者从CAR-T至莫妥珠单抗的中位时间显著长于未缓解者(P=0.006,未校正多重比较)。
  • 莫妥珠单抗治疗后,缓解者淋巴细胞计数为995 vs 未缓解者400个/μL(P=0.02)。
  • 缓解者CD4细胞中位变化73 vs 未缓解者-90个/μL(P=0.005),CD8细胞中位变化243 vs -103个/μL(P=0.004)。

核心结论

  • 这些发现提示既往CAR-T与双特异性抗体结局之间存在交互作用,并对CAR-T后双特异性抗体的最佳时机具有意义。

研究设计与样本

  • 利用曾接受CAR-T治疗并随后参加莫妥珠单抗1/2期研究的患者的临床数据和血样进行分析。
  • 30例患者具有基线和莫妥珠单抗1个周期后的配对样本。
  • 试验注册号为NCT02500407。

主要发现

  • 缓解者从CAR-T至莫妥珠单抗的中位时间显著长于未缓解者(P=0.006,未校正多重比较)。
  • 大多数患者(20/30)在CAR-T与莫妥珠单抗之间未接受 intervening 治疗,其余患者在方案规定的药物洗脱后接受1种 intervening 治疗。
  • 莫妥珠单抗治疗后,缓解者淋巴细胞计数为995 vs 未缓解者400个/μL(P=0.02)。
  • 缓解者CD4细胞中位变化为73 vs 未缓解者-90个/μL(P=0.005),CD8细胞中位变化为243 vs -103个/μL(P=0.004)。
  • 缓解者活化CD8细胞中位倍数变化为1.7(P=0.02);未缓解者CAR转基因水平相对下降(n=16;P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mosunetuzumab and other CD20/CD3 bispecific antibodies (BsAbs) have efficacy in B-cell lymphomas relapsing after or refractory to CD19-directed chimeric antigen receptor (CAR)-modified T cells (CAR-T). The optimal timing of BsAbs and biomarkers of BsAb response after CAR-T are unknown. We addressed these questions using clinical data and blood samples from patients previously treated with CAR-T and subsequently treated on a phase 1/2 study of mosunetuzumab. Thirty patients had paired samples at baseline and after 1 cycle of mosunetuzumab. The median time from CAR-T to mosunetuzumab was significantly longer for responding than for nonresponding patients (P = .006, unadjusted for multiple comparisons). Most patients (20/30) did not receive intervening therapy between CAR-T administration and mosunetuzumab. The remainder of patients received 1 intervening therapy after a protocol-mandated drug washout. After mosunetuzumab, responding patients had higher lymphocytes (995 vs 400 cells per μL; P = .02) and greater increases in CD4 and CD8 cells (median change, 73 vs -90 cells per μL [P = .005] and 243 vs -103 cells per μL [P = .004], respectively). Additionally, responding patients had an increase in activated CD8 cells (median fold change, 1.7; P = .02). Nonresponders had a relative decrease in CAR transgene levels (n = 16; P = .04). This is, to our knowledge, the first study to assess changes in lymphocytes, T cells, and CAR transgene levels in patients treated with BsAbs after CAR-T. These findings suggest an interaction between prior CAR-T and BsAb outcomes and have implications for optimal timing of BsAb after CAR-T. The trial was registered at www.ClinicalTrials.gov as #NCT02500407.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chong EA, Penuel E, Napier EB, et al. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025. PMID: 39571171. doi:10.1182/bloodadvances.2024013640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。